The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status
出版年份 2020 全文链接
标题
The different role of YKL-40 in glioblastoma is a function of MGMT promoter methylation status
作者
关键词
-
出版物
Cell Death & Disease
Volume 11, Issue 8, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2020-08-21
DOI
10.1038/s41419-020-02909-9
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Measured and genetically predicted plasma YKL-40 levels and melanoma mortality
- (2019) Hafsa Ismail et al. EUROPEAN JOURNAL OF CANCER
- DNA methylation-based classification of central nervous system tumours
- (2018) David Capper et al. NATURE
- Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma
- (2016) Michele Ceccarelli et al. CELL
- Prognostic and predictive value of YKL-40 in stage IIB-III melanoma
- (2016) Merete Krogh et al. MELANOMA RESEARCH
- Serum YKL-40 in Risk Assessment for Colorectal Cancer: A Prospective Study of 4,496 Subjects at Risk of Colorectal Cancer
- (2015) J. S. Johansen et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Withholding temozolomide in glioblastoma patients with unmethylatedMGMTpromoter—still a dilemma?: Table 1.
- (2015) Monika E. Hegi et al. NEURO-ONCOLOGY
- Combination of Oncolytic Herpes Simplex Viruses Armed with Angiostatin and IL-12 Enhances Antitumor Efficacy in Human Glioblastoma Models
- (2015) Wei Zhang et al. NEOPLASIA
- MGMT testing—the challenges for biomarker-based glioma treatment
- (2014) Wolfgang Wick et al. Nature Reviews Neurology
- Novel cancer-testis antigen expression on glioma cell lines derived from high-grade glioma patients
- (2014) YASUTO AKIYAMA et al. ONCOLOGY REPORTS
- Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
- (2014) A. P. Patel et al. SCIENCE
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
- (2013) Mark R. Gilbert et al. JOURNAL OF CLINICAL ONCOLOGY
- Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
- (2012) Annika Malmström et al. LANCET ONCOLOGY
- Oncolytic Virus-Mediated Manipulation of DNA Damage Responses: Synergy With Chemotherapy in Killing Glioblastoma Stem Cells
- (2011) Ryuichi Kanai et al. JNCI-Journal of the National Cancer Institute
- Bevacizumab With Angiostatin-armed oHSV Increases Antiangiogenesis and Decreases Bevacizumab-induced Invasion in U87 Glioma
- (2011) Wei Zhang et al. MOLECULAR THERAPY
- MEK-ERK Signaling Dictates DNA-Repair Gene MGMT Expression and Temozolomide Resistance of Stem-Like Glioblastoma Cells via the MDM2-p53 Axis
- (2011) Atsushi Sato et al. STEM CELLS
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
- (2010) Houtan Noushmehr et al. CANCER CELL
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
- (2010) Roel G.W. Verhaak et al. CANCER CELL
- γH2AX: a sensitive molecular marker of DNA damage and repair
- (2010) L-J Mah et al. LEUKEMIA
- Human Glioblastoma-Derived Cancer Stem Cells: Establishment of Invasive Glioma Models and Treatment with Oncolytic Herpes Simplex Virus Vectors
- (2009) H. Wakimoto et al. CANCER RESEARCH
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
- (2009) Michael Weller et al. Nature Reviews Neurology
- Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation With Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity
- (2008) Monika E. Hegi et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
- Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
- (2007) Thierry Gorlia et al. LANCET ONCOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started